Crossmark

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Crossref DOI link: https://doi.org/10.1186/s12944-021-01434-8

Published Online: 2021-02-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Komiya, Ichiro https://orcid.org/0000-0002-4965-4561
Yamamoto, Akira

Sunakawa, Suguru

Wakugami, Tamio
License Information

Text and Data Mining valid from 2021-02-20

Version of Record valid from 2021-02-20
More Information

Article History

Received: 1 December 2020

Accepted: 19 January 2021

First Online: 20 February 2021

Ethics approval and consent to participate

: In accordance with the declaration of Helsinki, this retrospective study was approved by the Ethics Committee of Medical Plaza Daido Central (approval number 34–2020). Because only the medical records were reviewed, this study was exempted from signing the informed consent.

: Regarding publication of the research results, we explained that we could not reveal personal information and obtained verbal consent from all target patients.

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below